The Pharmacology of T Cell Therapies

Adoptive cellular therapy using T cells with tumor specificity derived from either natural T cell receptors (TCRs) or an artificial chimeric antigen receptor (CAR) has reached late phase clinical testing, with two CAR T cell therapies achieving regulatory approval within the United States in 2017. The effective use of these therapies depends upon an understanding of their pharmacology, which is quite divergent from traditional small molecule or biologic drugs. We review the different types of T cell therapy under clinical development, the factors affecting cellular kinetics following infusion, and the relationship between these cellular kinetics and anti-cancer activity. We also discuss the toxicity associated with T cell therapies, with an emphasis on cytokine release syndrome and neurotoxicity, and the gaps in knowledge regarding these frequent and unique adverse effects.

• Publication year

  2018

• Venue

  Molecular Therapy: Methods & Clinical Development

• Publication date

  2018-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.omtm.2018.01.010PMID 29552577PMCID 5852291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

  2018cited by this paper
• Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

  2018cited by this paper
• Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

  2017cited by this paper
• Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors

  2017cited by this paper
• Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

  2017cited by this paper
• Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

  2017cited by this paper
• Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.

  2017cited by this paper
• Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.

  2017cited by this paper
• Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.

  2017cited by this paper
• Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

  2017cited by this paper
• Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

  2017cited by this paper
• Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

  2017cited by this paper
• Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells

  2017cited by this paper
• PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

  2017cited by this paper
• Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

  2017cited by this paper
• Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

  2017cited by this paper
• Increasing the safety and efficacy of chimeric antigen receptor T cell therapy

  2017cited by this paper
• The Principles of Engineering Immune Cells to Treat Cancer.

  2017cited by this paper
• A versatile system for rapid multiplex genome-edited CAR T cell generation

  2017cited by this paper
• High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients

  2017cited by this paper
• Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

  2017cited by this paper
• Transposons: Moving Forward from Preclinical Studies to Clinical Trials

  2017cited by this paper
• Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia

  2017cited by this paper
• The Promise of Chimeric Antigen Receptor T-Cell Therapy.

  2016cited by this paper
• Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

  2016cited by this paper
• A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

  2016cited by this paper
• Engineered T cells: the promise and challenges of cancer immunotherapy

  2016cited by this paper
• T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

  2016influential reference
• Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

  2016cited by this paper
• Domain-swapped T cell receptors improve the safety of TCR gene therapy

  2016cited by this paper
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

  2016influential reference
• Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

  2016cited by this paper
• Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

  2016cited by this paper
• Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

  2016cited by this paper
• Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

  2016cited by this paper
• Lentiviral vectors, two decades later

  2016cited by this paper
• Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).

  2016cited by this paper
• Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide

  2016cited by this paper
• Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia

  2016cited by this paper
• B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

  2016cited by this paper
• Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

  2016cited by this paper
• A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation.

  2016cited by this paper
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity.

  2015cited by this paper
• Retrovirus-based vectors for transient and permanent cell modification.

  2015cited by this paper
• First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia

  2015cited by this paper
• NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Viral Vectors for Gene Therapy: Translational and Clinical Outlook.

  2015cited by this paper
• ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Exploiting the curative potential of adoptive T‐cell therapy for cancer

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

  2013cited by this paper
• Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

  2013cited by this paper
• Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

  2013influential reference
• How to treat cancer

  2013cited by this paper
• Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.

  2012cited by this paper
• Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma

  2012cited by this paper
• Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

  2012cited by this paper
• New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28‐OX40 signalling

  2011cited by this paper
• A human memory T-cell subset with stem cell-like properties

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• T cell receptor gene therapy for cancer.

  2009cited by this paper
• Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

  2009cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009cited by this paper
• Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma

  2009cited by this paper
• Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

  2008cited by this paper
• Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

  2007cited by this paper
• Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration

  2007cited by this paper
• Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection1

  2006cited by this paper
• Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

  2005cited by this paper
• Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

  2002cited by this paper
• Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

  1999cited by this paper
• Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

  1998cited by this paper
• CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.

  1996cited by this paper
• Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

  1994cited by this paper
• Graft-versus-leukemia reactions after bone marrow transplantation.

  1990cited by this paper
• Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

  1987cited by this paper

• Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective

  2025cites this paper
• Clinical Pharmacology Characterization of the First‐In‐Class Oncolytic Viral Therapy T‐VEC in Adults and Pediatric Subjects

  2025cites this paper
• A universal chimeric antigen receptor (CAR)–fragment antibody binder (FAB) split system for cancer immunotherapy

  2025cites this paper
• A Critical Review of CAR-T Therapies for Glioblastoma: What's Wrong with the Current Attempts?

  2025cites this paper
• Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire

  2025cites this paper
• Small-molecule control of CAR T cells

  2025cites this paper
• Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.

  2025cites this paper
• Optimization of velocity receptor transduction in CAR T cells

  2025cites this paper
• Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy

  2024cites this paper
• Exploring cellular immunotherapy platforms in multiple myeloma

  2024cites this paper
• Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

  2024cites this paper
• CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production

  2024cites this paper
• An adjusted droplet digital PCR assay for quantification of vector copy number in CAR-T cell and TCR-T cell products

  2024cites this paper
• CAR T-cell therapy in acute myeloid leukemia

  2024cites this paper
• Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic

  2024cites this paper
• Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance

  2024cites this paper
• CAR-T cell therapy in advanced thyroid cancer: from basic to clinical

  2024cites this paper
• CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects

  2024cites this paper
• Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

  2024cites this paper
• CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.

  2023cites this paper
• Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells

  2023cites this paper
• CAR T-Cell therapy for the management of mantle cell lymphoma

  2023cites this paper
• CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma

  2023cites this paper
• High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.

  2023cites this paper
• CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma

  2022cites this paper
• Modeling and Simulation of CAR T cell Therapy in Chronic Lymphocytic Leukemia Patients

  2022cites this paper
• Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia

  2022cites this paper
• Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products.

  2022cites this paper
• Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

  2022cites this paper
• Emerging Trends in Immunotherapy for Cancer

  2022cites this paper
• Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy

  2022cites this paper
• Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells

  2022influential citation
• Cellular Kinetics: A Clinical and Computational Review of CAR-T Cell Pharmacology.

  2022cites this paper
• Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

  2022cites this paper
• Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells

  2022cites this paper
• Untangling the Knots of Regulatory T Cell Therapy in Solid Organ Transplantation

  2022cites this paper
• Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.

  2022cites this paper
• Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse.

  2021cites this paper
• Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

  2021cites this paper
• Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.

  2021cites this paper
• Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4

  2021cites this paper
• A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy

  2021cites this paper
• An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells.

  2021cites this paper
• CAR-T cell therapy: current limitations and potential strategies

  2021cites this paper
• Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products

  2021cites this paper
• On the road to eliminating long‐lived plasma cells—“are we there yet?”

  2021cites this paper
• Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma

  2021cites this paper
• Quantitative radio-thin-layer chromatography and positron emission tomography studies for measuring streptavidin transduced chimeric antigen receptor T cells.

  2021cites this paper
• Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells

  2021cites this paper
• Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency

  2021cites this paper
• Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

  2021cites this paper
• Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology

  2021influential citation
• Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models.

  2020cites this paper
• Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy

  2020cites this paper
• A multivariate, quantitative assay that disentangles key kinetic parameters of primary human T cell function in vitro

  2020cites this paper
• Chimeric Antigen Receptor (CAR) T-Cell Therapy: Case Histories of Significant Medical Advances

  2020cites this paper
• Application of Nanomaterials in Cancer Diagnosis, Drug Delivery, and Therapy

  2020cites this paper
• An Antigen‐Delivery Protein Nanoparticle Combined with Anti‐PD‐1 Checkpoint Inhibitor Has Curative Efficacy in an Aggressive Melanoma Model

  2020cites this paper
• Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells

  2020cites this paper
• Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source.

  2020cites this paper
• A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies

  2020cites this paper
• Improved harmonization of critical characterization assays across cell therapies.

  2020cites this paper
• Applications of Nanomaterials in Human Health

  2020cites this paper
• Reconstruction of cell spatial organization from single-cell RNA sequencing data based on ligand-receptor mediated self-assembly

  2020cites this paper
• Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice

  2020cites this paper
• Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma

  2020cites this paper
• Gene editing and CRISPR in the clinic: current and future perspectives

  2020cites this paper
• Chimeric antigen receptor T‐cell therapies: Optimising the dose

  2020influential citation
• CAR T-cell product performance in haematological malignancies before and after marketing authorisation.

  2020cites this paper
• Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors

  2019cites this paper
• Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model

  2019cites this paper
• Engineering strategies to overcome the current roadblocks in CAR T cell therapy

  2019cites this paper
• Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model

  2019cites this paper
• Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma

  2019influential citation
• Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics

  2019cites this paper
• CAR-T cell and Personalized Medicine.

  2019cites this paper
• Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies

  2019cites this paper
• CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV

  2019cites this paper
• Efficient gene transfer into T lymphocytes by fiber-modified human adenovirus 5

  2019cites this paper
• Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents.

  2019cites this paper
• Cytokine release syndrome. Reviewing a new entity in the intensive care unit.

  2019cites this paper
• Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.

  2019cites this paper
• Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma

  2019cites this paper
• Imaging CAR T cell therapy with PSMA-targeted positron emission tomography

  2019cites this paper
• Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

  2019cites this paper
• Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics.

  2019cites this paper
• Convergence of Cell Pharmacology and Drug Delivery

  2019cites this paper
• CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

  2019cites this paper
• Tolerance induction in hemophilia: innovation and accomplishments

  2018cites this paper
• Flow cytometry in cell-based pharmacokinetics or cellular kinetics in adoptive cell therapy.

  2018cites this paper
• The Pharmacology of Gene and Cell Therapy

  2018cites this paper
• Science Journals — AAAS

  2017cites this paper